Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March
Moderna (NASDAQ: MRNA) has hit a bit of a snag with the manufacturing of its COVID-19 vaccine. The company's fill-and-finish contractor, Catalent (NYSE: CTLT), is experiencing delays with some of the doses it's responsible for getting out the door. The companies didn't disclose exactly what was causing the delay.
"Fill and finish" is the last step in the manufacturing process and involves putting the vaccine into vials, slapping on labels, and other steps needed to go from a large batch of vaccine product to something healthcare workers can use. It's a relatively straightforward process but is still highly regulated by the Food and Drug Administration and agencies from other countries.
Image source: Getty Images.
Source Fool.com
